CN Patent
CN101437493B — 二肽基肽酶iv抑制剂制剂
Assigned to Boehringer Ingelheim International GmbH · Expires 2013-10-23 · 13y expired
What this patent protects
本发明涉及具有氨基的DPP IV抑制剂的药物组合物,其制备及其治疗糖尿病的用途。
USPTO Abstract
本发明涉及具有氨基的DPP IV抑制剂的药物组合物,其制备及其治疗糖尿病的用途。
Drugs covered by this patent
- Tradjenta (LINAGLIPTIN) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.